Isomorphic Labs Raises $5B Before Naming a Drug Candidate: What the Round Does and Doesn't Tell Us

November 18, 2026

Isomorphic Labs, the Alphabet-linked AI drug discovery company, said on November 17, 2026 that it has raised a $5 billion Series C. The round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor. In its announcement the company cited "continued significant investment from Alphabet" and participation from all existing investors. TechCrunch's report lists those backers as including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.

What is confirmed

  • Size and leads: $5 billion, co-led by Greenoaks and Sequoia Capital, per the company announcement and independent coverage including TechCrunch, Axios and Sifted.
  • Use of funds: The company says the money will go toward moving its first AI-designed drug candidates toward clinical trials and scaling its drug-design engine, IsoDDE.
  • Prior round: The raise follows a $2.1 billion Series B announced in May 2026.
  • Partners: TechCrunch reports the company has struck deals with Eli Lilly, Novartis and Johnson & Johnson.

What is not confirmed

Valuation. Isomorphic has not disclosed one. Bloomberg reported in early October that the company was in early talks at a valuation of roughly $40 to 50 billion, and BioCentury has cited rumors of up to $50 billion. Treat those figures as reports, not confirmed terms.

Preclinical performance. The company describes positive preclinical results in its announcement. Those are company statements and we have not seen independent validation.

The "record" label. BioCentury called the round the largest venture round in biotech history, surpassing Altos Labs' $3 billion, based on its own BCIQ database. We are attributing that ranking to BioCentury rather than asserting it ourselves. BioCentury also noted the round arrives before Isomorphic has publicly named a development candidate.

Analysis: what the round does and doesn't tell us

This section is our opinion and analysis.

What it suggests: investors are underwriting a platform and the compute and talent behind it, not a single pipeline asset. A round this size, before a named clinical candidate, is a bet that a drug-design engine can produce many candidates rather than one.

What it does not show: that the approach works in people. Clinical proof is still ahead, and the preclinical claims are the company's own. A large round also does not set a price on the company; without a disclosed valuation, outsiders cannot say what Alphabet's or the new investors' stakes imply.

Takeaway for founders

If you are building in AI-enabled biotech, this round points to capital concentrating in a few platform bets. Smaller teams are likely to be judged on a clear path to the clinic: a named candidate, a defined first indication, and milestones an outside party can check.

Sources: Isomorphic Labs announcement (Nov 17, 2026); TechCrunch (Nov 17, 2026); Axios Pro (Nov 17, 2026); Sifted (Nov 17, 2026); Bloomberg Law (Nov 17, 2026); BioCentury (Nov 18, 2026). This article is editorial content and is not sponsored. It is not investment advice.

Corrections or comment from the company or investors are welcome; reply to this site's editorial contact.

Jason Lim

Jason Lim

I wanted more than just survival—I wanted control, options, and a life on my terms. The obsession with this goal led me to several places and acquired unique skillsets, in order to accomplish my goals. I found the secrets in my rock bottom, now I want to share them with you

Instagram logo icon
Youtube logo icon
Back to Blog